Acadia Pharma (ACAD) Misses Q1 EPS by 9c

Acadia Pharma (NASDAQ: ACAD) reported Q1 EPS of ($0.57), $0.09 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $90.1 million versus the consensus estimate of $91.51 million.

“ACADIA entered 2020 with positive momentum. Successful execution of our commercial efforts led to continued strong performance of NUPLAZID® for Parkinson’s disease psychosis and our plans remain on track for delivering a potential second indication with pimavanserin for the treatment of DRP. We also continue to invest in our late-stage pipeline and business development opportunities to shape our mid and long-term growth strategy,” said Steve Davis, ACADIA’s Chief Executive Officer. “Our results this quarter reflect the dedication of our employees and I am proud of our team’s commitment to the patients we serve while adapting to the challenges of the global COVID-19 pandemic.”

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• UBS Reiterates Buy Rating on Linde (LIN) as Challenges in Helium Are 'Being Managed'
• StoneX on Mama’s Creations (MAMA): 'We Remain High-Conviction Buyers'